160 related articles for article (PubMed ID: 20686833)
21. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial.
Cheung AM; Tile L; Cardew S; Pruthi S; Robbins J; Tomlinson G; Kapral MK; Khosla S; Majumdar S; Erlandson M; Scher J; Hu H; Demaras A; Lickley L; Bordeleau L; Elser C; Ingle J; Richardson H; Goss PE
Lancet Oncol; 2012 Mar; 13(3):275-84. PubMed ID: 22318095
[TBL] [Abstract][Full Text] [Related]
22. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of discontinuing risedronate for patients with systemic lupus erythematosus: a prospective study.
Ishida T; Yoshida S; Kimura Y; Fujiki Y; Kotani T; Takeuchi T; Makino S; Arawaka S
Lupus; 2018 Sep; 27(10):1636-1643. PubMed ID: 29954283
[TBL] [Abstract][Full Text] [Related]
24. Changes in bone mineral density in newly diagnosed testicular cancer patients after anticancer treatment.
Willemse PM; Hamdy NA; de Kam ML; Burggraaf J; Osanto S
J Clin Endocrinol Metab; 2014 Nov; 99(11):4101-8. PubMed ID: 25119312
[TBL] [Abstract][Full Text] [Related]
25. The Benefit of Menopausal Hormone Therapy on Bone Density and Microarchitecture Persists After its Withdrawal.
Papadakis G; Hans D; Gonzalez-Rodriguez E; Vollenweider P; Waeber G; Marques-Vidal PM; Lamy O
J Clin Endocrinol Metab; 2016 Dec; 101(12):5004-5011. PubMed ID: 27854548
[TBL] [Abstract][Full Text] [Related]
26. Incidence of chemotherapy-induced ovarian failure in premenopausal women undergoing chemotherapy for breast cancer.
Tiong V; Rozita AM; Taib NA; Yip CH; Ng CH
World J Surg; 2014 Sep; 38(9):2288-96. PubMed ID: 24700093
[TBL] [Abstract][Full Text] [Related]
27. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.
Coleman RE; Banks LM; Girgis SI; Kilburn LS; Vrdoljak E; Fox J; Cawthorn SJ; Patel A; Snowdon CF; Hall E; Bliss JM; Coombes RC;
Lancet Oncol; 2007 Feb; 8(2):119-27. PubMed ID: 17267326
[TBL] [Abstract][Full Text] [Related]
28. Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07).
Zaman K; Thürlimann B; Huober J; Schönenberger A; Pagani O; Lüthi J; Simcock M; Giobbie-Hurder A; Berthod G; Genton C; Brauchli P; Aebi S;
Ann Oncol; 2012 Jun; 23(6):1474-81. PubMed ID: 22003243
[TBL] [Abstract][Full Text] [Related]
29. Osteoporosis in women with breast cancer and its effect on quality of life: a pilot study.
Turan Y; Kocaaga Z; Karakoyun-Celik O; Gurgan A; Duransoy A
J BUON; 2009; 14(2):239-43. PubMed ID: 19650173
[TBL] [Abstract][Full Text] [Related]
30. Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results.
Nakatsukasa K; Koyama H; Ouchi Y; Ono H; Sakaguchi K; Matsuda T; Kato M; Ishikawa T; Yamada K; Yoshimura M; Koizumi K; Sakurai T; Shigematsu H; Takahashi S; Taira S; Suzuki M; Narui K; Niikura N; Hasegawa Y; Miura D; Konishi E; Taguchi T;
Breast Cancer; 2019 Jan; 26(1):106-112. PubMed ID: 30054855
[TBL] [Abstract][Full Text] [Related]
31. Impact of chemotherapy followed by aromatase inhibitors on bone health of women with ER-positive early breast cancer in real world clinical settings in Greece: Results of the POCHARBI trial conducted by the Hellenic Society of Breast Surgeons.
Markopoulos C; Koukouras D; Venizelos V; Karyda I; Xepapadakis G; Misitzis J; Kalogerakos K; Poulakaki F; Natsiopoulos J; Zobolas V; Savidou C; Antonopoulou Z; Tzoracoleftherakis E
Breast; 2016 Jun; 27():27-34. PubMed ID: 27212697
[TBL] [Abstract][Full Text] [Related]
32. Assessment of ovarian failure and osteoporosis in premenopausal breast cancer survivors.
McCune JS; Games DM; Espirito JL
J Oncol Pharm Pract; 2005 Jun; 11(2):37-43. PubMed ID: 16460603
[TBL] [Abstract][Full Text] [Related]
33. Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopausal women with breast cancer treatment-induced bone loss: results of the ProBONE II substudy.
Kalder M; Kyvernitakis I; Albert US; Baier-Ebert M; Hadji P
Osteoporos Int; 2015 Jan; 26(1):353-60. PubMed ID: 25381047
[TBL] [Abstract][Full Text] [Related]
34. Risks factors for low bone mineral density in pre-menopausal Mexican women with systemic lupus erythematosus.
Mendoza-Pinto C; García-Carrasco M; Sandoval-Cruz H; Escárcega RO; Jiménez-Hernández M; Etchegaray-Morales I; Soto-Vega E; Muñoz-Guarneros M; López-Colombo A; Delezé-Hinojosa M; Cervera R
Clin Rheumatol; 2009 Jan; 28(1):65-70. PubMed ID: 18670734
[TBL] [Abstract][Full Text] [Related]
35. Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy.
Kwan ML; Yao S; Laurent CA; Roh JM; Quesenberry CP; Kushi LH; Lo JC
Breast Cancer Res Treat; 2018 Apr; 168(2):523-530. PubMed ID: 29249058
[TBL] [Abstract][Full Text] [Related]
36. Bone mineral density in women with cytotoxic-induced ovarian failure.
Howell SJ; Berger G; Adams JE; Shalet SM
Clin Endocrinol (Oxf); 1998 Sep; 49(3):397-402. PubMed ID: 9861333
[TBL] [Abstract][Full Text] [Related]
37. A prospective study of bone loss in menopausal Australian-born women.
Guthrie JR; Ebeling PR; Hopper JL; Barrett-Connor E; Dennerstein L; Dudley EC; Burger HG; Wark JD
Osteoporos Int; 1998; 8(3):282-90. PubMed ID: 9797914
[TBL] [Abstract][Full Text] [Related]
38. Changes on bone mineral density after adjuvant treatment in women with non-metastatic breast cancer.
Rodríguez-Rodríguez LM; Rodríguez-Rodríguez EM; Oramas-Rodríguez JM; Santolaria-Fernandez F; Llanos M; Cruz J; Martínez A; González-Reimers E; Gómez A; Batista N
Breast Cancer Res Treat; 2005 Sep; 93(1):75-83. PubMed ID: 16184462
[TBL] [Abstract][Full Text] [Related]
39. Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer.
Bruning PF; Pit MJ; de Jong-Bakker M; van den Ende A; Hart A; van Enk A
Br J Cancer; 1990 Feb; 61(2):308-10. PubMed ID: 2310683
[TBL] [Abstract][Full Text] [Related]
40. Baseline bone mineral density of the total lumbar spine may predict for chemotherapy-induced ovarian failure.
Shapiro CL; Phillips G; Van Poznak CH; Jackson R; Leboff MS; Woodard S; Lemeshow S
Breast Cancer Res Treat; 2005 Mar; 90(1):41-6. PubMed ID: 15770525
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
